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Introduction: Adherence to long-acting bronchodilator therapy for management of chronic 
obstructive pulmonary disease (COPD) is a critical clinical and cost issue. Low adherence is 
associated with relatively higher exacerbation rates and illness burden.
Purpose: To compare adherence between patients with COPD initiating therapy on 
tiotropium or fluticasone/salmeterol and examine the association between adherence and 
respiratory-related costs.
Patients and methods: This retrospective claims data analysis evaluated patients initiating 
tiotropium or combination fluticasone/salmeterol from December 1, 2004 to December 31, 
2005. Patients had $1 COPD diagnosis (International Classification of Diseases, 9th Revision, 
Clinical Modification [ICD-9-CM] 491.xx, 492.x, 496) and were observed during 6-month 
pre-index and variable (12–18-month) post-index periods. Outcomes were adherence to and 
discontinuation of therapy, and respiratory-related inpatient, medical, and total health care costs. 
Adherence was medication possession ratio $0.80. Discontinuation, adherence, and costs were 
analyzed with Cox proportional hazards regression, logistic regression, and generalized linear 
model regressions, respectively. Regressions controlled for demographic, sociodemographic, 
and health status factors.
Results: The study population comprised 1561 tiotropium and 2976 fluticasone/salmeterol 
patients. In unadjusted comparisons: 19.5% and 8.5% of tiotropium and fluticasone/salmeterol 
patients, respectively, were adherent (P , 0.001); tiotropium patients versus fluticasone/salme-
terol patients had higher mean respiratory-related pharmacy costs (US$1080 versus US$974, 
P = 0.002) and health care costs (US$3751 versus US$2932, P = 0.031). Regression analysis 
showed tiotropium patients were 31.6% less likely to discontinue therapy (95% confidence interval 
[CI]: 0.64–0.73) and had 2.25 times higher odds of adherence (CI: 1.85–2.73) versus fluticasone/
salmeterol patients. The associations between index therapy and costs were not significant. Adher-
ence versus nonadherence was associated with: 46.9% higher health care costs (CI: 1.13–1.91); 
37.1% lower medical costs (CI: 0.43–0.91); and 53.4% lower inpatient costs (CI: 0.30–0.72).
Conclusion: Patients with COPD initiating long-acting bronchodilator therapy were more likely 
to be adherent to tiotropium than to fluticasone/salmeterol. Adherence to either tiotropium or 
to fluticasone/salmeterol was associated with lower respiratory-related medical and inpatient 
costs, and with higher respiratory-related total health care costs.
Keywords: bronchodilator agents, health care costs, medication adherence, COPD, retrospec-
tive studies
Introduction
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by airflow 
limitation that is “not fully reversible” and progressive lung function decline.1,2 Chronic Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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bronchitis and emphysema are the two main components of 
COPD.1,2 COPD is the fourth leading cause of death in the 
United States,1 and it is estimated that it will be the third 
leading cause of death by 2020.3 Approximately 12 million 
US adults are diagnosed with COPD, and another 12 million 
may have the disease but remain undiagnosed.4 The burden 
of COPD on the United States health care system is consid-
erable. Estimates from research conducted in 2000 showed 
that COPD was associated with approximately 1.5 million 
emergency department visits, 726,000 hospitalizations, and 
119,000 deaths per year.5 A more recent estimate linked 
COPD with US$42.6 billion in US health care costs and lost 
productivity in 2007.6
Current approaches to managing COPD are aimed at 
treating both the symptoms and the underlying pulmonary 
inflammation and bronchoconstriction associated with the 
disorder. Pharmacologic therapy for COPD includes short-
acting and long-acting beta-agonists (SABAs, LABAs), 
anticholinergic agents, methylxanthines, and inhaled 
glucocorticosteroids.1,2,7 The 2009 update to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines,2 as well as other national guidelines,8 recommend 
treatment with long-acting bronchodilators, including once-
daily anticholinergic tiotropium, for management of stable 
Stage II moderate COPD. The GOLD guidelines specify 
that treatment with inhaled glucocorticosteroids, alone or in 
combination with inhaled beta-agonists, may be indicated 
for the management of more severe COPD.2
Nevertheless, despite the widespread availability of 
practice guidelines for outpatient management of COPD, 
research indicates that these guidelines are underutilized in 
“real-world” clinical practice.9,10 A survey of 784 primary 
care physicians who actively treated COPD patients revealed 
that only 55% were cognizant of COPD treatment guidelines 
and 25% factored guidelines into their treatment decisions. 
Additionally, 32% of the primary care physicians treated 
patients with mild COPD with inhaled corticosteroids.9
Furthermore, several studies have shown that even when 
these guidelines are followed, adherence to recommended 
therapy is poor among COPD patients,11 as is often the case 
with individuals requiring long-term therapy for chronic 
diseases.12,13 The underuse of COPD medications has been 
reported in numerous studies, both in clinical trial settings 
and in “real-world” clinical practice settings.14–19 Results 
of the Lung Health Study, a double-blind, multicenter, 
randomized controlled trial of smoking intervention and 
bronchodilator use in COPD patients, showed a decline in 
self-reported adherence from 70% of patients at 4-month 
follow up to 60% over the next 18 months.20 Overall, the 
results of   studies   conducted in a variety of settings indi-
cate that   average adherence to COPD regimens is 50% or 
lower.13,14,16–18,21 The literature indicates that: (1) physicians 
who treat patients with COPD do not uniformly adhere to 
treatment guidelines; and (2) patients frequently are not 
adherent to bronchodilator therapy.
Adherence to COPD treatments, particularly to long-
acting bronchodilators, is a critical clinical and health 
economics issue affecting the management of stable COPD 
because of its well documented impact on a wide variety of 
health outcomes.12,16,22 Greater adherence to COPD medica-
tions has been shown to be associated with lower rates of 
exacerbations, fewer emergency room visits and inpatient 
hospitalizations, shorter lengths of inpatient stays, less inef-
ficient escalation of therapy, lower health care expenditures, 
and higher quality of life.15,16,22–27
Most of the published literature documenting adherence 
to COPD therapies examines medications that have been 
on the market for several years (eg, short-acting anticho-
linergics, inhaled corticosteroids, LABAs) or results from 
clinical trials. There is little information on adherence to 
newer long-acting bronchodilators.
Study objectives
The objectives of this retrospective claims study were to: 
(1) compare adherence between COPD patients initiating 
long-acting bronchodilator therapy on tiotropium or flutica-
sone/salmeterol; and (2) examine the association between 
adherence to these therapies and respiratory-related costs. 
We hypothesized that: (1) adherence levels would differ 
between patients treated with tiotropium and those treated 
with fluticasone/salmeterol; and (2) better adherence to long-
acting bronchodilator therapy would be associated with lower 
respiratory-related medical costs. To our knowledge, there are 
no studies in the published literature that compare adherence 
to these two long-acting bronchodilator therapies.
Materials and methods
Data source
The retrospective administrative claims data used in this study 
included medical claims, pharmacy claims, and eligibility 
information from a large, national US health plan. The plan 
provides fully insured coverage for professional (eg, physi-
cian), facility (eg, hospital), and outpatient prescription 
medication services. Professional and facility claims include 
International Classification of Diseases, 9th Revision, 
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procedure codes, Current Procedural Terminology, Version 
4 (CPT-4) procedure codes, Healthcare Common Procedure 
Coding System (HCPCS) procedure codes, site of service 
codes, provider specialty codes, and health plan and patient 
costs. Outpatient pharmacy claims provide National Drug 
Codes (NDC) for dispensed medications, quantity dispensed, 
drug strength, days supply, provider specialty code, and health 
plan and patient costs.
The individuals covered by this health plan, about 
14 million in 2007, are geographically diverse across the 
United States, with greatest representation in the South and 
Midwest US census regions. Prior to the commencement 
of this study, claims data were linked at the individual level 
with an external database that contains measures of sociode-
mographic characteristics, including race and ethnicity, and 
household income; after this linkage, all patient identification 
information (eg, date of birth) was removed and replaced 
with the unique anonymous patient identification numbers 
associated with individual health plan enrollees in the claims. 
The sociodemographic data measures were generated by 
a combination of self-report, modeling, census data, and 
a variety of other individual-level and population-level data 
sources. Although identifying information was not required 
to link the sociodemographic data with the claims data, we 
obtained approval from a privacy board to ensure that use 
of the sociodemographic data would not risk individual 
patient identification. All study data were made unidentifi-
able and accessed with protocols compliant with the Health 
Insurance Portability and Accountability Act enacted by the 
US Congress in 1996.
Subject identification
The study population comprised commercial health plan 
members diagnosed with COPD and initiated on tiotropium 
or fluticasone/salmeterol. (This study was originally designed 
to include patients initiated on long-acting bronchodilators, 
including salmeterol and formoterol, as well as on tiotropium 
or fluticasone/salmeterol. Ultimately, the numbers of patients 
initiated on salmeterol (N = 128) or formoterol (N = 111) 
after application of the selection criteria were very small. 
Consequently, only tiotropium (N = 1561) and fluticasone/
salmeterol (N = 2976) cohorts were retained and analyzed.) 
All patients had at least one pharmacy claim for one of these 
two medications during the identification period December 1, 
2004 through December 31, 2005. The date of the first tiotro-
pium or fluticasone/salmeterol pharmacy claim was defined 
as the “index date”, and the medication on the index prescrip-
tion claim was defined as the “index therapy”. All patients 
were at least 40 years old during the year of the index date, 
and had 6 months of pre-index date (“baseline”) and at least 
12 months, up to 18 months, of post-index date   (“follow up”) 
continuous enrollment with medical and pharmacy benefits. 
In addition, patients were required to have at least one medi-
cal claim with a primary or secondary ICD-9-CM diagnosis 
code for COPD (ICD-9-CM 491.xx, 492.x, 496) during 
the baseline period or within 60 days after the index date. 
Patients with any pharmacy claims for tiotropium, flutica-
sone/salmeterol, salmeterol, or formoterol during the baseline 
period were excluded from the study population in order to 
focus on those initiating long-acting therapy. Patients with 
medical claims with primary or secondary ICD-9-CM codes 
for asthma (ICD-9-CM 493.xx), cystic fibrosis (ICD-9-CM 
277.0x), or lung cancer (ICD-9-CM 162.2–162.9, 197.0, 
212.3, 231.2, 235.7, 239.1) at any time during the baseline 
or follow up periods also were excluded.
cohort assignment
Patients were divided into tiotropium and fluticasone/sal-
meterol cohorts. Patients were assigned to the tiotropium 
cohort if their index therapy was tiotropium; if they also had 
a pharmacy claim for fluticasone/salmeterol within 2 weeks 
after the index date, they remained in the tiotropium cohort 
if they had at least two pharmacy claims for tiotropium and 
only one claim for fluticasone/salmeterol throughout follow 
up (including index date). Conversely, patients were assigned 
to the fluticasone/salmeterol cohort if their index therapy was 
fluticasone/salmeterol; if they had a claim for tiotropium 
within the 2 weeks after the index date, they remained in 
the cohort if they had at least two fluticasone/salmeterol 
claims and only one tiotropium claim throughout follow up. 
Patients who had pharmacy claims each for tiotropium and 
fluticasone/salmeterol within 2 weeks after the index date 
and at least two claims each for fluticasone/salmeterol and 
tiotropium throughout follow up (ie, patients who might have 
been concurrently treated with tiotropium and fluticasone/
salmeterol) were excluded in order to limit the study popula-
tion to patients initiated on only one of the therapies.
Variables
Outcomes
Adherence and therapy discontinuation with the index 
therapy were assessed during the follow up period inclu-
sive of the index date. Adherence was measured with a 
continuous medication possession ratio (MPR): (cumula-
tive days supply of the index therapy during follow up)/
(number of days of follow up). The number of days spent in Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
378
Halpern et al
inpatient facilities was subtracted from both the   numerator 
and denominator of the MPR based on the assumption 
that COPD therapy was administered during any inpatient 
stay.28 MPR values greater than 1.0 were truncated to 1.0. 
The continuous MPR value (between 0.0 and 1.0) was also 
converted to a binary indicator such that MPR $ 0.80 was 
“adherent”29 and MPR , 0.80 was “nonadherent”. Therapy 
discontinuation was defined as a lapse, or “gap”, in therapy, 
and occurred when more than 30 days elapsed between the 
“run-out” date (ie, the date of the last fill plus its days sup-
ply) of an index therapy fill and the next refill or the end of 
the follow up period. Discontinuation was also defined with 
a 60 day gap threshold. Both measures of discontinuation 
were adjusted for early refills.
Respiratory-related cost outcome measures included 
medical costs, outpatient pharmacy costs, total health care 
(medical + outpatient pharmacy) costs, and inpatient costs 
associated with a broad variety of respiratory conditions. 
Inpatient costs were a subset of the respiratory-related medi-
cal costs. Respiratory-related medical care was identified 
from medical claims with primary diagnoses for respiratory 
conditions or respiratory failure; or diagnoses associated 
with respiratory conditions or respiratory failure secondary 
to primary diagnoses for cardiac conditions. The ICD-9-CM 
diagnosis codes used to identify respiratory conditions 
or respiratory failure and cardiac conditions are shown in 
Appendix A and Appendix B, respectively. Respiratory-
related pharmacy costs represented costs for medications 
associated with the designated respiratory conditions, and 
were based on pharmacy claims for tiotropium, fluticasone/
salmeterol, LABAs (salmeterol, formoterol), SABAs (isopro-
terenol, isoetharine, metaproterenol, terbutaline, albuterol, 
bitolterol, pirbuterol, levalbuterol), short-acting anticholin-
ergics (ipratropium), theophylline, inhaled corticosteroids 
(beclomethasone, flunisolide, dexamethasone, triamcinolone, 
mometasone, budesonide, fluticasone), and oral prednisone. 
Costs were the sum of health plan-paid and patient-paid 
amounts (ie, not charged amounts) and were adjusted for 
inflation up to 2006 using the medical care cost component 
of the Consumer Price Index.
Cost variables were not standardized to a uniform period 
(eg, per patient per month or annualized) because length of 
follow up was uniform within the study population. The mean 
(standard deviation [SD]) lengths of follow up for the tiotro-
pium and fluticasone/salmeterol cohorts were 502.7 (58.5) 
days and 508.0 (57.1) days, respectively; these lengths of 
follow up, although significantly different (P = 0.004, data not 
shown), were nevertheless quite close. The median length of 
follow up for both cohorts was 547 days, which also was the 
maximum length of follow up. The lengths of follow up at the 
25th percentile for the tiotropium and fluticasone/salmeterol 
cohorts were 459.0 and 470.5 days, respectively.
Demographic, sociodemographic, and clinical 
characteristics
Demographic variables (age, gender, and geographic region) 
were captured from the enrollment data. Race was mea-
sured as a binary indicator, white/nonwhite, where “white” 
denotes non-Hispanic Caucasian. Household income was 
measured as a categorical variable. Clinical characteristics 
were measured during the baseline period and included: 
indication of respiratory complication; comorbid conditions 
(hypertension, heart disease, lipid metabolism, respiratory 
infection); Charlson Comorbidity Index (CCI) score; and use 
of SABAs or short-acting anticholinergics, corticosteroids, 
and oxygen services. Baseline respiratory complication was 
a binary flag to identify patients who had at least one baseline 
respiratory-related inpatient stay or emergency department 
visit. This measure was modeled on a similar measure of 
acute COPD exacerbation, also based on respiratory-related 
hospitalization or emergency department visit, used by 
Chrischilles et al;30 their definition of “respiratory-related” 
included diagnoses of COPD, asthma, emphysema, chronic 
or acute bronchitis, and pneumonia. We generalized the 
measure of respiratory complication to include the broader 
diagnostic criteria for “respiratory-related” used in this 
study. The comorbidities of hypertension, heart disease, 
disorders of lipid metabolism, and respiratory infection 
were identified with the Clinical Classification Software 
managed by the Agency for Healthcare Research and 
Quality.31 CCI was based on the Quan et al32 update of the 
Deyo et al33 adaptation of the original Charlson et al index.34 
SABA use was a binary indicator to identify patients with 
at least one SABA or short-acting anticholinergic pharmacy 
claim. Corticosteroid use was a binary indicator based on 
inhaled corticosteroid or oral prednisone pharmacy claims. 
Use of oxygen services was identified with medical claims 
containing HCPCS codes A4611–A4629, E0424–E0486, 
E0550–E0585, E1353–E1406, or S8120–S8121. In addition, 
a binary indicator showed whether the index therapy fill 
(on index date) was associated with a pulmonology specialty 
code as a proxy for intensity of services consumption.
statistical analysis
All study variables were analyzed descriptively. Results 
were stratified by cohort; respiratory-related costs also were Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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stratified by adherence within cohort. T-tests were used 
to examine differences between unadjusted mean values 
of   continuous variables, accounting for unequal variance 
as appropriate, and chi-square tests were used to evaluate 
unadjusted differences in proportions.
Regression analysis was employed to analyze factors 
associated with discontinuation, adherence, and respiratory-
related health care costs, medical costs, and inpatient costs, 
while controlling for covariates. Time to first discontinu-
ation (both 30 day and 60 day gap criteria) was modeled 
using Cox proportional hazards regression. Adherence was 
modeled with logistic regression. Generalized linear model 
(GLM) regressions with log link and gamma distribution 
were estimated to evaluate respiratory-related costs. 
Respiratory-related medical costs and inpatient costs were 
analyzed with two-part cost models: the first part was a 
logistic regression to model whether the patient had any 
respiratory-related medical or inpatient costs (.US$0); the 
second part was GLM to model actual costs among those 
who had cost .US$0. The gamma distribution used in all 
GLM regressions was selected based on the Park test.35   
A two-part cost model was not necessary to model respi-
ratory-related health care costs because all patients had 
cost .US$0. Independent variables included: index therapy 
cohort; age category; gender; pulmonologist-prescribed index 
therapy fill; baseline respiratory complication; CCI score; 
baseline SABA, corticosteroid, and oxygen utilization; and 
baseline comorbid conditions. The binary adherence indicator 
was also an independent variable in the cost models.
Sensitivity testing was conducted for the adherence and 
cost regressions. An alternative threshold of MPR $0.70 
was employed for the logistic regression to model adherence. 
Additional cost regressions that added geographic region 
indicators as covariates and that excluded the adherence 
(MPR $0.80) indicator were estimated. All analysis was 
performed with SAS, Version 9, and Stata, Version 9.
Results
Descriptive analysis results
The study population numbered 4537 patients, of whom 
1561 initiated tiotropium therapy and 2976 initiated 
fluticasone/salmeterol therapy; patient selection and attrition 
are shown in Figure 1. Demographic and sociodemographic 
characteristics of the study population, by cohort, are 
shown in Table 1. The mean (SD) ages within cohorts were 
62.0 (10.4) years in the tiotropium cohort and 60.3 (10.7) 
years in the fluticasone/salmeterol cohort (data not shown, 
P , 0.001). Consistent with the national coverage of the 
health plan, about three-quarters of each cohort was enrolled 
in the South or Midwest regions. Approximately 60% of 
patients in each cohort had household income levels lower 
than US$70,000. There was a small but significant difference 
in the proportion of white patients by cohort: 85.8% in the 
tiotropium cohort compared with 83.5% in the fluticasone/
salmeterol cohort (P = 0.037).
Baseline clinical characteristics are presented in Table 2. 
There were few significant differences between the tiotro-
pium and fluticasone/salmeterol cohorts. Higher proportions 
of the tiotropium cohort had SABA use and oxygen use 
during baseline: 36.9% of the tiotropium cohort had at least 
Individuals ≥40 years old with ≥1 claim for long-
acting bronchodilator during identification period
12/1/04–12/31/05
N = 257,815 
Continuous enrollment for 6-month baseline and
≥12-month follow-up
N = 132,725 (51.5% retained) 
No medical claims with asthma, cystic fibrosis, or
lung cancer diagnoses
N = 8,260 (3.2% retained) 
Initiating long-acting bronchodilator therapy on
index date
N = 4, 537 (1.8% retained)  
≥1 medical claim with primary or secondary COPD
diagnosis
N = 19,828 (7.7% retained) 
Individuals who can be assigned to tiotropium and
fluticasone/salmeterol cohorts
(ie, not salmeterol or formoterol, not concurrent
tiotropium + fluticasone/salmeterol therapy at
index date)
N = 6,977 (2.7% retained)   
Figure 1 study population selection and attrition.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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one SABA fill compared with 32.5% of the fluticasone/
salmeterol cohort (P = 0.003), and 17.1% of the tiotropium 
cohort used oxygen services compared with 12.7% of the 
fluticasone/salmeterol cohort (P , 0.001). In addition, a 
significantly higher proportion of the tiotropium cohort had 
a CCI score of 1 (50.8% versus 47.0% in the fluticasone/
salmeterol cohort, P = 0.013) or a CCI score of 4 (5.0% 
versus 3.5% of fluticasone/salmeterol patients, P = 0.014); 
conversely, a significantly lower proportion of tiotropium 
patients (11.5%) had a CCI score of 0 compared with the 
fluticasone/salmeterol cohort (19.2%, P , 0.001).
Tiotropium patients had higher mean unadjusted adher-
ence during follow up, on average, than did fluticasone/
salmeterol patients. The mean (SD) unadjusted MPRs for 
the tiotropium and fluticasone/salmeterol cohorts were 
0.38 (0.34) and 0.26 (0.28), respectively (P , 0.001, data 
not shown). (MPR may also be adjusted for time spent in 
inpatient facilities by subtracting the number of inpatient 
days only from the denominator.28 We tested the sensitivity 
of our MPR measure by calculating adherence as (cumulative 
days supply of index therapy during follow-up)/(length of 
follow-up – inpatient days). MPR was not sensitive to this 
variation in measurement. The mean (SD) MPR over the entire 
study population when number of inpatient days was subtracted 
from both the numerator and denominator was 0.30 (0.31). 
The revised mean (SD) MPR was 0.31 (0.31)).
The proportions of patients with discontinuations mea-
sured with 30 day and 60 day gaps are displayed in Figure 2. 
The great majority of all patients had at least one gap in 
index therapy during their follow up periods; 84.8% of 
tiotropium patients had at least one minimum 30-day gap 
compared with 94.1% of fluticasone/salmeterol patients 
(P , 0.001), and 77.6% and 88.9% of tiotropium and 
fluticasone/  salmeterol patients, respectively, had minimum 
60 day gaps (P , 0.001). The low overall continuous adher-
ence and high rate of discontinuation account for the low 
proportions of adherent patients, also shown in Figure 2. 
Less than 20% of each cohort was adherent, although 
the tiotropium cohort exhibited a higher adherence rate 
(19.5%) than did the fluticasone/salmeterol cohort (8.5%, 
P , 0.001).
Mean follow up respiratory-related costs are shown in 
Tables 3 and 4. Table 3 provides a comparison of unad-
justed mean costs between the study cohorts. The tiotro-
pium cohort had significantly higher unadjusted mean 
Table 1 Demographic and sociodemographic characteristics by 
index therapy cohort
Tiotropium  
(N = 1561)
Fluticasone/ 
salmeterol  
(N = 2976)
P-value
N % N %
Age category
  40–54 367 23.5 935 31.4 ,0.001
  55–64 673 43.1 1,161 39.0 0.007
  65–74 301 19.3 509 17.1 0.069
  75+ 220 14.1 371 12.5 0.122
Gender
  Male 883 56.6 1,526 51.3 0.001
US census region
  northeast 145 9.3 288 9.7 0.672
  Midwest 450 28.8 911 30.6 0.213
  south 769 49.3 1,350 45.4 0.012
  West 197 12.6 427 14.3 0.108
Household income (USD)
 , $30,000 336 21.5 560 18.8 0.030
  $30,000–$49,999 306 19.6 543 18.3 0.266
  $50,000–$69,999 332 21.3 645 21.7 0.753
  $70,000–$99,999 238 15.3 509 17.1 0.109
  $$100,000 247 15.8 528 17.7 0.103
  Missing 102 6.5 191 6.4 0.880
Race
  Whitea 1340 85.8 2484 83.5 0.037
  non-whiteb 199 12.8 450 15.1 0.030
  Missing 22 1.4 42 1.4 0.996
Notes: anon-Hispanic caucasian; bnon-white includes Hispanic; African American, 
Asian, other race/ethnicity.
Table  2  Baseline  clinical  characteristics  by  index  therapy 
cohort
Tiotropium  
(N = 1561)
Fluticasone/ 
salmeterol  
(N = 2976)
P-value
N % N %
Respiratory complication
    Present during  
baseline
202 12.9 380 12.8 0.870
Comorbid conditions
  Hypertension 688 44.1 1277 42.9 0.452
  Heart disease 703 45.0 1223 41.1 0.011
    Disorders of lipid  
metabolism
613 39.3 1114 37.4 0.226
    respiratory  
infections
588 37.7 1238 41.6 0.010
Use of breathing agents
    Use of short-acting  
beta-agonist
576 36.9 967 32.5 0.003
  Use of corticosteroid 303 19.4 509 17.1 0.054
  Use of oxygen 267 17.1 377 12.7 ,0.001
Charlson Comorbidity Index score
 0 179 11.5 572 19.2 ,0.001
 1 793 50.8 1397 47.0 0.013
 2 298 19.1 510 17.1 0.102
 3 148 9.5 275 9.2 0.791
 4 78 5.0 104 3.5 0.014
 $ 5 65 4.1 118 4.0 0.746Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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[SD] respiratory-related pharmacy costs (US$1080 [1096]) 
compared with the fluticasone/salmeterol cohort (US$974 
[1124], P = 0.002). The tiotropium cohort also had higher 
mean unadjusted respiratory-related health care costs 
(US$3751 [13,462]) relative to the fluticasone/salmeterol 
cohort (US$2932 [9137], P = 0.031). Table 4 provides within-
cohort comparisons of unadjusted mean respiratory-related 
cost outcomes stratified by adherence. Unadjusted mean 
pharmacy costs were higher among adherent patients in both 
cohorts (US$2405 [1048] among adherent tiotropium patients 
versus US$759 [835] among nonadherent tiotropium patients, 
P , 0.001; US$3148 [1153] and US$772 [882] among 
adherent and nonadherent fluticasone/salmeterol patients, 
respectively, P , 0.001). There were no other significant dif-
ferences within the tiotropium cohort. Within the fluticasone/
salmeterol cohort, nonadherent patients had significantly 
higher unadjusted mean respiratory-related inpatient costs 
(US$1307 [8714]) compared with adherent patients (US$604 
[2441], P = 0.002), while adherent patients had higher 
unadjusted total health care costs (US$4650 [3752]) versus 
nonadherent patients (US$2772 [9468], P = 0.002).
Multivariate analysis results
The hazard ratios associated with the index therapy cohort 
indicator (reference = tiotropium cohort) from both Cox 
proportional hazards regressions are displayed in Figure 3. 
The hazard ratios for the cohort indicator were 0.68 (95% 
confidence interval [CI]: 0.64–0.73, P , 0.01) for the 
30 day gap criterion and 0.72 (CI: 0.67–0.77, P , 0.01) for 
the 60 day gap criterion. Thus, the fluticasone/salmeterol 
cohort was about 39%–47% more likely to discontinue with 
either gap threshold compared with the tiotropium cohort. 
Post-estimation tests of the proportional hazards assumption 
based on Schoenfeld residuals showed that the likelihood 
84.8%
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88.9%
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Figure 2 Unadjusted discontinuation and adherence by index therapy cohort.
Table 3 Unadjusted respiratory-related costs by index therapy 
cohort
Tiotropium  
(N = 1561)
Fluticasone/ 
salmeterol  
(N = 2976)
P-value
Mean SD Mean SD
inpatient stay  
costs
1646 11,074 1248 8368 0.213
Medical costs 2671 13,334 1958 8956 0.058
Outpatient  
pharmacy costs
1080 1096 974 1124 0.002
Health care  
costs
3751 13,462 2932 9137 0.031
Note: All costs were measured in 2006 Us dollars and during follow-up period. 
inpatient stay costs are costs associated with inpatient facility stays; medical costs 
are costs for all medical services, including inpatient costs; health care costs are the 
sum of medical and outpatient pharmacy costs.
Abbreviation: sD, standard deviation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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of discontinuation was proportional for the cohort indicator 
throughout the follow up period.
Figure 4 provides odds ratios (ORs) for the cohort indica-
tor (reference = tiotropium) from logistic regressions used 
to model adherence at the MPR $0.80 and MPR $0.70 
thresholds. The results for both adherence thresholds showed 
that the tiotropium cohort had significantly higher odds of 
adherence relative to the fluticasone/salmeterol cohort. The 
OR for the cohort indicator at the MPR $0.80 adherence 
threshold was 2.25 (CI: 1.85–2.73, P , 0.01); the OR at the 
MPR $0.70 threshold was 2.03 (CI: 1.70–2.41, P , 0.01). 
Post-estimation Hosmer-Lemeshow tests showed good 
model fit, as did receiver operating characteristic (ROC) 
analysis (ROC between 0.72 and 0.73).
The coefficients for the cohort and adherence indicators 
from the cost regressions are shown in Table 5. The cohort 
indicator was not significant in any of the cost regressions. 
The adherence indicator (reference = MPR $ 0.80) was 
significant in four of the five regressions. Adherence was 
associated with 46.9% higher respiratory-related health care   
Table 4 Unadjusted respiratory-related costs by adherence level
Tiotropium P-value Fluticasone/salmeterol P-value
Adherenta 
(N = 305)
Nonadherent 
(N = 1256)
Adherent 
(N = 253)
Nonadherent 
(N = 2723)
Mean SD Mean SD Mean SD Mean SD
inpatient stay costs 1412 14,523 1703 10,066 0.741 604 2441 1307 8714 0.002
Medical costs 2539 14,897 2703 12,932 0.860 1502 3328 2001 9307 0.070
Outpatient pharmacy costs 2405 1048 759 835 ,0.001 3148 1153 772 882 ,0.001
Health care costs 4945 15,076 3462 13,030 0.115 4650 3752 2772 9468 0.002
Notes: All costs were measured in 2006 Us dollars and during follow-up period. inpatient stay costs are costs associated with inpatient facility stays; medical costs are costs 
for all medical services, including inpatient costs; health care costs are the sum of medical and outpatient pharmacy costs. aAdherent = continuous medication possession 
ratio $0.80 
Abbreviation: sD, standard deviation.
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Figure 3 regression-adjusted discontinuation: index therapy cohort. 
Notes: controlled for: age category; gender; baseline respiratory complication; baseline charlson comorbidity index score; household income; race; pulmonologist-
prescribed index therapy fill; baseline use of corticosteroid, short-acting beta- agonist, oxygen; baseline hypertension, heart disease, respiratory infection, lipid metabolism 
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(medical + outpatient pharmacy) costs compared with non-
adherence (CI: 1.13–1.91, P , 0.01). Adherence was associated 
with 42.2% higher odds of incurring any   respiratory-related 
medical cost .$0 (CI: 1.07–1.90 P , 0.05) and was associ-
ated with lower respiratory-related medical costs among 
patients with any medical costs (cost ratio: 0.63, CI: 0.43–
0.91, P , 0.05). Additionally, adherence was associated 
with significantly lower respiratory-related inpatient costs 
among patients with inpatient cost .$0 (cost ratio: 0.47, 
CI: 0.30–0.72, P , 0.01). There was no effect on cost regres-
sion results with respect to the index therapy cohort as a result 
of the sensitivity testing (adding geographic region indicators, 
excluding adherence indicator; results not shown).
Discussion
We examined medical claims data for patients with COPD 
who initiated tiotropium or fluticasone/salmeterol therapy 
and observed their index therapy treatment outcomes and 
respiratory-related cost outcomes for 12–18 months after 
initiation. Regression analysis showed a strong association 
between index therapy cohort and the odds of adherence, as 
well as between cohort and gaps in therapy. The adherence 
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Figure 4 regression-adjusted adherence: index therapy cohort. 
Notes: controlled for: age category; gender; baseline respiratory complication; baseline charlson comorbidity index score; household income; race; pulmonologist-prescribed 
index therapy fill; baseline use of corticosteroid, short-acting beta- agonist, oxygen; baseline hypertension, heart disease, respiratory infection, lipid metabolism disorder.
Abbreviation: MPr, medication possession ratio.
Table 5 regression-adjusted respiratory-related costs: index therapy cohort and adherence
Health care  
costs
Medical costs Inpatient costs
Cost ratio 
(95% CI)
Odds ratio 
(95% CI)
Cost ratio 
(95% CI)
Odds ratio 
(95% CI)
Cost ratio 
(95% CI)
cohort (tiotropium = 1) 0.999 
(0.831–1.202)
0.925 
(0.777–1.102)
1.061 
(0.809–1.392)
0.905 
(0.724–1.131)
1.175 
(0.849–1.627)
Adherent to index therapy  
(MPr $ 0.80)
1.469 
(1.131–1.908)a
1.422 
(1.067–1.896)b
0.629 
(0.434–0.912)b
0.883 
(0.648–1.202)
0.466 
(0.303–0.719)a
Observations 4244 4244 3478 4244 441
Notes: aP , 0.01; b0.01# P , 0.05. controlled for: age category; gender; baseline respiratory complication; baseline charlson comorbidity index score; household income; 
race; pulmonologist-prescribed index therapy fill; baseline line of corticosteroid, short-acting beta-agonist, oxygen; baseline hypertension, heart disease, respiratory infection, 
lipid metabolism disorder. All costs were measured in 2006 Us dollars and during follow-up period.
Abbreviations: CI, confidence interval; MPR, medication possession ratio.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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regression confirmed our hypothesis of a difference in 
adherence between the index therapy cohorts. This difference 
may be attributable in part to the relatively more convenient 
dosing schedule for tiotropium (one inhalation per day) 
  compared with that for fluticasone/salmeterol (two inhala-
tions per day).36,37 Tiotropium patients had higher odds of 
adherence (MPR $ 0.80), and were significantly less likely 
to have gaps in their therapy compared with the fluticasone/
salmeterol cohort after controlling for demographic and 
baseline clinical characteristics.
The tiotropium cohort had higher mean unadjusted 
respiratory-related outpatient pharmacy and total respiratory-
related health care costs compared with the fluticasone/salme-
terol cohort. The higher mean respiratory-related pharmacy 
cost could have been a function of higher adherence in the 
tiotropium cohort, and the higher mean respiratory-related 
total health care costs, in turn, could have been, in part, 
a function of the higher mean pharmacy costs and sicker 
patients based on demographic and clinical characteristics 
that we were able to measure (Tables 1 and 2). There was, 
however, no regression-adjusted association between index 
therapy cohort and any of the cost outcomes; thus, the signifi-
cant differences in mean respiratory-related total health care 
costs between the index therapy cohorts, shown in Table 2, did 
not persist when factors associated with costs were controlled 
for in the multivariate analysis. Despite higher adherence 
levels, respiratory-related costs for the tiotropium cohort 
were not significantly different from those in the fluticasone/
salmeterol cohort.
In the first part of the two-part respiratory-related 
medical cost model, adherence was associated with 
higher odds of having a medical cost (ie, cost .US$0). 
This result indicates that patients who are more adherent 
to tiotropium or fluticasone/salmeterol have higher odds 
of medical services consumption. One explanation for 
this result is that adherent patients have more frequent 
contact with the medical system than do nonadherent 
patients because adherent patients obtain more prescrip-
tions for their therapies. Moreover, it is possible that, in 
general, patients who are adherent are also more active in 
seeking medical care in addition to prescriptions. In the 
second part of the two-part model, adherence was associ-
ated with lower respiratory-related medical costs among 
patients who incurred any respiratory-related medical 
costs, as hypothesized. Thus, the two-part model suggests 
that: 1) among all patients, adherent patients had higher 
odds of receiving medical treatment for respiratory-related 
conditions; and 2) among the subset of patients who had 
a respiratory-related medical cost, those costs were lower 
among adherent patients.
Adherence was associated with higher respiratory-related 
health care costs, most likely as a function of higher odds of 
incurring respiratory-related medical costs (shown in part 
1 of the respiratory-related medical cost model) as well as 
higher respiratory-related pharmacy costs among adherent 
patients (as shown in Table 4). Even though the association 
between adherence and respiratory-related pharmacy costs 
was not evaluated with regression analysis, the difference in 
unadjusted mean respiratory-related costs is large enough 
that one can reasonably surmise that they are an important 
cost driver.
Finally, adherence was associated with lower respi-
ratory-related inpatient costs among patients with any 
  respiratory-related inpatient costs. Respiratory-related 
  inpatient costs were a subset of respiratory-related medical 
costs. Mean respiratory-related inpatient costs accounted for 
61.6% and 63.7% of mean respiratory-related medical costs 
in the tiotropium and fluticasone/salmeterol cohorts, respec-
tively (Table 3). This suggests that the association between 
adherence to long-acting bronchodilators and respiratory-
related medical costs was partially driven by the association 
between adherence and respiratory-related inpatient costs. 
Adherence was not associated with the odds of having a 
respiratory-related inpatient cost. The lack of a significant 
effect for adherence may be attributable to insufficient sample 
size or unobserved factors that also may affect the odds of a 
respiratory-related inpatient stay.
The result that better adherence to therapy is associated 
with lower respiratory-related medical and inpatient costs 
is consistent with the relationships between adherence and 
cost outcomes in the literature. Also consistent with the 
literature were the tiotropium and fluticasone/salmeterol 
adherence estimates within our study population; the mean 
MPRs in our study population – 0.38 in the tiotropium 
cohort and 0.26 in the fluticasone/salmeterol cohort – align 
with adherence estimates of 10%–40% in clinical practice 
documented by Bourbeau and Bartlett.14 Low adherence to 
inhaled medications is not unique to COPD; it has also been 
documented among individuals using inhaled therapies for 
treatment of asthma.15,38
Barriers to improved adherence to inhaled bronchodila-
tor therapy are well documented and include complexity of 
regimen, frequency of dosing, and polypharmacy, as well as 
patient characteristics such as change in lifestyle, behavior, 
trust and belief in provider and treatment efficacy, concern 
about side effects, forgetfulness, or misunderstanding of Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Dovepress
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dosing instruction.13,14,16,21,39 The capacity to achieve better 
adherence to inhaled therapies by addressing some of the 
barriers to good adherence should result in better outcomes 
for COPD patients. Interventions to improve adherence can 
include: patient education, both to bolster understanding of 
COPD and the impact of inhaled therapies in retarding dis-
ease progress and to ensure that patients receive reinforced 
instruction in appropriate medication administration; strate-
gies, developed with patients, to make adherence easier (eg, 
timing inhaler administration to coincide with other daily 
activities); and structured interactions with patients empha-
sizing active self-management.13,14
It is also worth noting, however, that improved adher-
ence may not result in reduced overall health care expendi-
tures. We found adherence, relative to nonadherence, was 
associated with higher respiratory-related health care costs. 
Similarly, Delea et al found that increased adherence to fluti-
casone/salmeterol was associated with higher asthma-related 
costs.12 These results should be interpreted carefully insofar 
as they are condition-specific costs, and not overall health 
care expenditures. Future research should evaluate the impact 
of improved adherence to long-term COPD therapies on total 
health care expenditures as well as on indirect costs, such as 
gains in productivity from delayed or prevented disability.
The results of this study should be interpreted in light of 
several limitations. There are inherent limitations in admin-
istrative claims data. We cannot observe whether medica-
tions were used as prescribed; this may affect the accuracy 
of therapy outcomes. The presence of a diagnosis code on a 
medical claim does not necessarily confirm a clinical condi-
tion such as COPD, as the diagnosis code may be incorrect or 
the result of rule-out. Costs were defined as costs incurred by 
the health plan and the patient; costs covered by a third-party 
payer were not available from the data. Lack of third-party 
coverage data is principally a concern for subjects at least 
65 years old who may have both traditional Medicare and 
commercial health plan coverage. Thus, some costs may be 
underestimated. Claims data do not contain clinical infor-
mation, such as forced expiratory volume or spirometry test 
results, that would allow us to measure COPD severity or 
other characteristics associated with costs. There was some 
claims data-based evidence pointing to a potential difference 
in health status and COPD severity between the tiotropium 
and fluticasone/salmeterol cohorts (ie, higher CCI score and 
higher proportions of patients with baseline SABA and oxy-
gen use in the tiotropium cohort), but it is difficult to assess 
clinically important differences in the absence of clinical 
measures not found in administrative claims. Moreover, the 
relationship between adherence and clinical outcomes could 
not be measured with these data. We did, however, control 
for the available measures of health status and COPD severity 
in the regression analyses.
There were also some limitations in the study design 
and measurement. The study design excluded patients with 
baseline use of any long-acting bronchodilator therapy. 
Consequently, the study population could have excluded 
patients who had failed on prior bronchodilator treat-
ment. We examined the data and found that 46 patients 
who initiated tiotropium and 43 patients who initiated 
fluticasone/salmeterol had at least one fill of a nonindex 
long-acting bronchodilator during the baseline period. 
When those 46 and 43 patients were added to the tiotro-
pium and fluticasone/salmeterol cohorts, respectively, the 
distribution of age category, gender, and rates of baseline 
respiratory complications, SABA use, and oxygen use (data 
not shown) across cohorts stayed virtually the same as 
those shown in Tables 1 and 2. The only difference for 
which the significance level changed was that between the 
proportions of tiotropium patients (19.9%) and fluticasone/
salmeterol patients (17.3%) with baseline corticosteroid use 
(P = 0.026). Therefore, the exclusion of patients with any 
baseline long-acting bronchodilator use was unlikely to have 
changed the analysis results. It is possible that regression 
results were affected by some degree of selection bias with 
respect to assignment of patients into the tiotropium and 
fluticasone/salmeterol cohorts. It is likely that coefficients 
were affected by omitted, unmeasured (and unavailable) 
variables associated with providers’ decisions to initiate 
patients on tiotropium or fluticasone/salmeterol, eg, physi-
cians’ assessments of potential side effects, experience with 
tiotropium or fluticasone/salmeterol in other patients, or 
simple preference. Cost outcomes were measured over vari-
able lengths of follow up, ranging from 12 to 18 months. The 
lengths of follow up were very close between the cohorts, 
as described previously, so it is unlikely that this influenced 
the comparisons; and, respiratory-related costs pertained to 
a variety of respiratory disorders. Therefore, it is likely that 
only a proportion of the costs reported are attributable to 
the treatment of COPD. Nevertheless, COPD patients are 
likely to have concomitant respiratory disorders, and these 
costs should provide a good estimate of overall expenditures 
associated with respiratory-related care.
Finally, the results of this analysis cannot be generalized 
to individuals with COPD who began treatment on tiotro-
pium or fluticasone/salmeterol after previous long-acting 
bronchodilator therapy or to those treated with salmeterol Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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or formoterol. Moreover, these results are not generalizable 
to patients with COPD and comorbid asthma.
Conclusion
Overall, less than 20% of patients with COPD who initiated 
long-acting bronchodilator therapy were adherent to their 
therapies. Patients initiating tiotropium therapy, however, 
were more than twice as likely to be adherent than were 
those initiating fluticasone/salmeterol. The majority of all 
patients (at least 84%) experienced a minimum 30 day gap 
in therapy, although patients initiating on fluticasone/salme-
terol were significantly more likely to discontinue therapy 
than were those initiating tiotropium. Adherence to either 
tiotropium or fluticasone/salmeterol was associated with 
lower respiratory-related medical costs and inpatient costs, 
while there were no associations between index therapy 
cohort and respiratory-related cost outcomes. Adherence is 
an important treatment objective that is crucial for prevent-
ing COPD-related exacerbations and preserving respiratory 
function. Nevertheless, it is important to recognize that 
improved adherence may be associated with higher overall 
expenditures. Further research should model the impact of 
improved adherence to COPD long-acting bronchodilator 
therapy on overall direct and indirect costs.
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Appendix  A.  icD-9-cM  Diagnosis  codes  for  respiratory 
conditions or respiratory Failure
Respiratory Condition ICD-9-CM Code
Acute respiratory infection 466.xx
Pneumonia 480.x–487.0
chronic bronchitis 490–491.xx
emphysema 492.x
Bronchiectasis 494.x
Pneumonitis and pneumoconiosis 495.x, 500–508.x
chronic obstructive pulmonary disease 496
empyema, pleurisy, and pneumothorax 510.x–512.x
respiratory failure 518.81–518.84
Abscess of lung and mediastinum 513.x
Pulmonary congestion and hypostasis 514
Post-inflammatory pulmonary fibrosis 515
Other alveolar and parietoalveolar pneumonopathy 516.x
Pulmonary collapse 518.0
Pulmonary eosinophilia 518.3
Acute edema of lung, unspecified 518.4
Pulmonary insufficiency following trauma or surgery 518.5
Allergic bronchopulmonary aspergillosis 518.6
Transfusion-related acute lung injury 518.7
Other diseases of the lung, not elsewhere classified 518.89
Other diseases of the respiratory system 519.xx
Note: Asthma would have been added as a respiratory condition; however, patients 
with medical claims with diagnosis codes for asthma were excluded from the study 
population.
Appendix  B.  icD-9-cM  Diagnosis  codes  for  cardiac 
conditions
Cardiac Condition ICD-9-CM 
Code
Diseases of mitral valve 394.x
Diseases of aortic valve 395.x
Diseases of mitral and aortic valves 396.x
rheumatic heart failure (congestive) 398.91
Hypertensive heart disease 402.xx
Hypertensive heart and chronic kidney disease 404.xx
Acute myocardial infarction 410.xx
Acute pulmonary heart disease 415.xx
chronic pulmonary heart disease 416.x
Other diseases of pulmonary circulation 417.x
Other diseases of endocardium 424.xx
cardiomyopathy 425.x
Heart failure 428.xx
Takotsubo syndrome 429.83